Tags

Type your tag names separated by a space and hit enter

Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Int J Clin Pract 2007; 61(8):1337-48IJ

Abstract

AIMS

This was a post hoc analysis to determine whether baseline severity of depression influenced the efficacy of duloxetine in treating major depressive disorder (MDD) and to better characterise the symptom response profile for duloxetine in patients with mild, moderate or more severe depression.

METHODS

Data were pooled from four double-blind, placebo-controlled studies in which outpatients with MDD were randomised to duloxetine (60 mg/day) or placebo for 8-9 weeks. Patients were retrospectively stratified according to baseline 17-item Hamilton Depression Rating scale (HAMD17) total scores: mild=total score<or=19 (duloxetine, n=246; placebo, n=184); moderate=20-24 (duloxetine, n=333; placebo, n=217); severe=25+ (duloxetine, n=127; placebo, n=87).

RESULTS

Duloxetine produced significantly greater baseline-to-end-point improvement vs. placebo (p<0.05) on the HAMD17 total score, Maier and retardation subscales, HAMD17 items 1 (depressed mood), 7 (work and activities) and 10 (psychic anxiety) in all three patient cohorts. The largest effect sizes were observed in assessments of core emotional depressive symptoms. A significant improvement for duloxetine vs. placebo was not observed for sleep-related symptoms at end-point or genital symptoms at any time point during acute treatment. With respect to the time course of depressive symptom improvement, the data show that regardless of baseline severity, the most rapid and consistent improvement for duloxetine compared with placebo was observed in the core symptoms of MDD (measured by the Maier subscale).

CONCLUSION

Regardless of baseline MDD severity, duloxetine at one dose (60 mg/day) produced a significant improvement compared with placebo on the core emotional symptoms of MDD.

Authors+Show Affiliations

Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, and McLean Hospital, Belmont, MA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

17627710

Citation

Shelton, R C., et al. "Patterns of Depressive Symptom Response in Duloxetine-treated Outpatients With Mild, Moderate or More Severe Depression." International Journal of Clinical Practice, vol. 61, no. 8, 2007, pp. 1337-48.
Shelton RC, Prakash A, Mallinckrodt CH, et al. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract. 2007;61(8):1337-48.
Shelton, R. C., Prakash, A., Mallinckrodt, C. H., Wohlreich, M. M., Raskin, J., Robinson, M. J., & Detke, M. J. (2007). Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. International Journal of Clinical Practice, 61(8), pp. 1337-48.
Shelton RC, et al. Patterns of Depressive Symptom Response in Duloxetine-treated Outpatients With Mild, Moderate or More Severe Depression. Int J Clin Pract. 2007;61(8):1337-48. PubMed PMID: 17627710.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. AU - Shelton,R C, AU - Prakash,A, AU - Mallinckrodt,C H, AU - Wohlreich,M M, AU - Raskin,J, AU - Robinson,M J, AU - Detke,M J, PY - 2007/7/14/pubmed PY - 2007/12/15/medline PY - 2007/7/14/entrez SP - 1337 EP - 48 JF - International journal of clinical practice JO - Int. J. Clin. Pract. VL - 61 IS - 8 N2 - AIMS: This was a post hoc analysis to determine whether baseline severity of depression influenced the efficacy of duloxetine in treating major depressive disorder (MDD) and to better characterise the symptom response profile for duloxetine in patients with mild, moderate or more severe depression. METHODS: Data were pooled from four double-blind, placebo-controlled studies in which outpatients with MDD were randomised to duloxetine (60 mg/day) or placebo for 8-9 weeks. Patients were retrospectively stratified according to baseline 17-item Hamilton Depression Rating scale (HAMD17) total scores: mild=total score<or=19 (duloxetine, n=246; placebo, n=184); moderate=20-24 (duloxetine, n=333; placebo, n=217); severe=25+ (duloxetine, n=127; placebo, n=87). RESULTS: Duloxetine produced significantly greater baseline-to-end-point improvement vs. placebo (p<0.05) on the HAMD17 total score, Maier and retardation subscales, HAMD17 items 1 (depressed mood), 7 (work and activities) and 10 (psychic anxiety) in all three patient cohorts. The largest effect sizes were observed in assessments of core emotional depressive symptoms. A significant improvement for duloxetine vs. placebo was not observed for sleep-related symptoms at end-point or genital symptoms at any time point during acute treatment. With respect to the time course of depressive symptom improvement, the data show that regardless of baseline severity, the most rapid and consistent improvement for duloxetine compared with placebo was observed in the core symptoms of MDD (measured by the Maier subscale). CONCLUSION: Regardless of baseline MDD severity, duloxetine at one dose (60 mg/day) produced a significant improvement compared with placebo on the core emotional symptoms of MDD. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/17627710/Patterns_of_depressive_symptom_response_in_duloxetine_treated_outpatients_with_mild_moderate_or_more_severe_depression_ L2 - https://doi.org/10.1111/j.1742-1241.2007.01444.x DB - PRIME DP - Unbound Medicine ER -